CN Patent

CN111205286B — 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用

Assigned to Suzhou Institute Of Drug Innovation Shanghai Institute Of Materia Medica Chinese Academy Of Sciences · Expires 2022-12-13 · 3y expired

What this patent protects

本发明公开一种作为KRAS G12C突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用，本发明化合物具有通式(I)所述结构。本发明所述的化合物相对于现有化合物对KRAS G12C突变导致的恶性肿瘤具有更高的选择性；显示了更长的半衰期，具有更好的代谢稳定性；更高的暴露量和更好的口服生物利用度以及更显著的抗肿瘤活性；

USPTO Abstract

本发明公开一种作为KRAS G12C突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用，本发明化合物具有通式(I)所述结构。本发明所述的化合物相对于现有化合物对KRAS G12C突变导致的恶性肿瘤具有更高的选择性；显示了更长的半衰期，具有更好的代谢稳定性；更高的暴露量和更好的口服生物利用度以及更显著的抗肿瘤活性；

Drugs covered by this patent

Patent Metadata

Patent number
CN111205286B
Jurisdiction
CN
Classification
—
Expires
2022-12-13
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Institute Of Drug Innovation Shanghai Institute Of Materia Medica Chinese Academy Of Sciences
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.